Results for Thrombocytopenia

1 - 10 of 15

Dr. Lambert's research focuses on understanding the mechanisms of inherited and acquired thrombocytopenia in pediatric patients. Using clinical translational methods to link discovery in rare platelet disorders with optimizing next-generation sequencing for clinical practice, she has been involved in the Undiagnosed Disease Network Program and the Frontier Program in Immune Dysregulation, incorporating genetics of platelet disorders and immunohematology.

E-mail:

lambertm [at] chop.edu

Stella T. Chou, MD

Dr. Chou focuses on regenerative blood cellular therapy, the mechanisms of normal human hematopoietic development, and the pathophysiology of pediatric hematologic diseases.

E-mail:

chous [at] chop.edu

Lubica Rauova, MD, PhD

Dr. Rauova is a researcher in the Division of Hematology at CHOP and a research associate professor of Pediatrics in the Perelman School of Medicine at the University of Pennsylvania. Her research focuses on the molecular and cellular interactions involved in hemostasis and thrombosis.

E-mail:

lubica [at] chop.edu

Julia T. Warren, MD, PhD

Dr. Warren studies normal and aberrant hematopoiesis, with a special interest in granulopoiesis. Her research aims to understand the pathogenesis of severe congenital neutropenia and its risk for malignant transformation. She has a clinical interest in neutropenia syndromes including clinical trials.

E-mail:

warrenjt [at] chop.edu

Enhancing the Effectiveness of NETs to Trap Bacteria

Published on

Jan 4, 2021

in Cornerstone Blog

Researchers work to enhance the body’s immune response to contain infection locally and prevent systemic bacterial spread.

New Grant Awarded to Study Mechanisms of Clotting

Published on

Dec 21, 2018

in Cornerstone Blog

“The problem with too much clotting is by far one of the most staggering medical issues in the Western world,” Dr. Krishnaswamy said. See what he and his colleagues are doing to combat this deadly disease.

Targeting Abnormal Signals Suggests Novel Method to Treat a Rare Childhood Blood Disease

Published on

Oct 9, 2018

in Press Releases

In Animal Study, CHOP Hematologist Restores Blood Cell Function in Fanconi Anemia

Diversity Makes a Difference: Q&A With Brian Estevez, PhD, New Diversity Fellow

Published on

Jan 25, 2017

in Cornerstone Blog

Looking at a scientific problem from new and different perspectives is what research is all about, which is why Children's Hospital of Philadelphia's Research Institute is dedicated to cultivating a more diverse workforce. "We value diversity within our research community and it is undoubtedly part of what makes us successful," wrote Bryan A. Wolf, MD, PhD, Chief Scientific Officer and Director

Rare Disease Project Makes Progress, Empowers

Published on

Apr 22, 2014

in Cornerstone Blog

In the U.S., a disease is considered rare if it affects fewer than 200,000 people. Many rare diseases have genetic origins, and almost 70 percent of Americans affected by a rare disease are children, according to the National Organization for Rare Disorders (NORD).

Dova Study for Children with Immune Thrombocytopenia (ITP)

The Dova study is for children below 18 years with primary Immune Thrombocytopenia (ITP) who have had an insufficient response to previous treatment.